Combination Therapy for Treatment of Leukemia
AssigneeSt. George's Hospital Medical School
InventorsVikram Mathews, Sanjeev Krishna
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of leukemia, (e.g. acute myeloid leukemia, AML) using a triple combination of: arsenic trioxide; iron; and an artemisinin, such as artesunate.
Claims28
A pharmaceutical composition which comprises:
- (a) arsenic trioxide;
- (b) iron;
- and
- (c) an artemisinin;
- for use in treating leukemia.
Arsenic trioxide for use in treating leukemia by co-administration with iron and an artemisinin.
Iron for use in treating leukemia by co-administration with arsenic trioxide and an artemisinin.
An artemisinin for use in treating leukemia by co-administration with arsenic trioxide and iron.
A method of treating a patient suffering from leukemia, which method comprises co-administering to said patient arsenic trioxide, iron and an artemisinin.
A product comprising (a) arsenic trioxide, (b) iron, and (c) an artemisinin, as a combined preparation for simultaneous, concurrent, separate or sequential use in the treatment of a patient suffering from leukemia.
Use of arsenic trioxide in the manufacture of a medicament for the treatment of leukemia by co-administration with iron and an artemisinin.
Use of iron in the manufacture of a medicament for the treatment of leukemia by co-administration with arsenic trioxide and an artemisinin.
Use of an artemisinin in the manufacture of a medicament for the treatment of leukemia by co-administration with arsenic trioxide and iron.
A pharmaceutical composition which comprises:
- (a) arsenic trioxide;
- (b) iron;
- and
- (c) an artemisinin.
A kit of parts which comprises:
- (a) arsenic trioxide;
- (b) iron;
- and
- (c) an artemisinin;
- wherein said components (a), (b) and (c) are each formulated in a separate pharmaceutical composition or wherein any two of the components (a), (b) and (c) are formulated together in a first pharmaceutical composition and the remaining component is formulated in a second pharmaceutical composition.
Dependencies are inferred from the claim text.